Celularity, Inc. (NASDAQ:CELU) Short Interest Up 40.1% in March

Celularity, Inc. (NASDAQ:CELU) was the target of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 433,481 shares, a growth of 40.1% from the February 26th total of 309,422 shares. Based on an average daily volume of 724,831 shares, the days-to-cover ratio is presently 0.6 days. Currently, 1.8% of the company’s shares are short sold.

Celularity Price Performance

Shares of CELU stock traded up $0.04 during trading hours on Monday, reaching $1.24. The company had a trading volume of 8,450 shares, compared to its average volume of 162,131. The company has a market cap of $35.62 million, a price-to-earnings ratio of -0.37 and a beta of 0.79. The business has a fifty day simple moving average of $1.26 and a 200-day simple moving average of $1.60. Celularity has a 12 month low of $1.01 and a 12 month high of $4.35.

Hedge Funds Weigh In On Celularity

Institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in shares of Celularity during the fourth quarter valued at about $33,000. Acadian Asset Management LLC bought a new position in shares of Celularity in the first quarter valued at approximately $34,000. Jane Street Group LLC purchased a new position in Celularity during the fourth quarter valued at approximately $46,000. Geode Capital Management LLC grew its stake in Celularity by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock valued at $178,000 after acquiring an additional 20,876 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Celularity by 35.3% during the 3rd quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock worth $1,401,000 after acquiring an additional 176,518 shares during the period. 19.02% of the stock is owned by institutional investors.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.